Phase II Study of NIS793 with and without Spartalizumab in Combination with Gemcitabine/Nab-paclitaxel compared to Gemcitabine/Nab-paclitaxel alone in Patients with Untreated Pancreatic Adenocarcinoma
Summary
The purpose of this phase II trial is to evaluate the safety and efficacy of NIS793 with and without spartalizumab in combination with gemcitabine and nab-paclitaxel compared to gemcitabine and nap-paclitaxel alone in patients with untreated metastatic pancreatic cancer.
General Information
NCT#: NCT04390763
Study ID: CNIS793B12201
Trial Phase: Phase II
Trial Sponsor: Novartis Pharmaceuticals
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, NIS793